|
產品描述： PS-48 是 phosphoinositide-dependent protein kinase-1 (PDK1) 的變構激活劑 |
|
靶點：
PDK1;PDK |
體內研究：
In vivo, the PDK1 agonist PS48 can maintain the bone mass of mice treated with dexamethasone |
|
細胞實驗：
Cell lines: MC3T3-E1 cells Concentrations: 5 μM Incubation Time: -- Method: MC3T3-E1 cells are cultured in an osteogenic differentiation medium containing 4 mM glycerophosphate and 25 μg/mL ascorbic acid until 70% confluency. Dexamethasone (final concentration of ethanol, 0.01%, vol/vol) at different concentrations is then added to the osteogenic differentiation medium for 14 days. The culture medium is replaced every two days. MC3T3-E1 cells are cultured in a culture medium containing 10?7 M dexamethasone supplemented with or without PS48 (5 μM). |
|
動物實驗：
Animal Models: 8-week-old male C57BL/6J mice Dosages: -- Administration: -- |
參考文獻：
1. Valerie Hindie, et al.Nat Chem Biol. 2009 Oct;5(10):758-64. 2. Wen-Ning Xu, et al. Front Endocrinol (Lausanne). 2020 Jan 28;10:922. |
|
溶解性：
Soluble in DMSO、Ethanol |
|
保存條件：
-20℃ |
配置溶液濃度參考：
|
1mg |
5mg |
10mg |
| 1 mM |
3.487 ml |
17.437 ml |
34.873 ml |
| 5 mM |
0.697 ml |
3.487 ml |
6.975 ml |
| 10 mM |
0.349 ml |
1.744 ml |
3.487 ml |
| 50 mM |
0.07 ml |
0.349 ml |
0.697 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京